Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses

References

• Ramage G, Martinez JP, Lopez-Ribot JL. Candida biofilms on implanted biomaterials: A clinically significant problem. FEMS Yeast Res 2006; 6: 979–986.
   PubMed Web of Science ®Google Scholar
• Mavor AL, Thewes S, Hube B. Systemic fungal infections caused by Candida species: Epidemiology, infection process and virulence attributes. Curr Drug Targets 2005; 6: 863–874.
   PubMed Web of Science ®Google Scholar
• Kuhn DM, Ghannoum MA. Candida biofilms: Antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004; 5: 186-197.
   PubMedGoogle Scholar
• Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004; 350: 1422–1429.
   PubMed Web of Science ®Google Scholar
• Fohrer C, Fornecker L, Nivoix Y, . Antifungal combination treatment: A future perspective. Int J Antimicrob Agents 2006; 1 (Suppl.27): 25–30.
   Google Scholar
• Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents 2007; 30: 108–117.
   PubMed Web of Science ®Google Scholar
• Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. J Infect Chemother 2009; 15: 1–5.
   PubMed Web of Science ®Google Scholar
• Bachmann SP, Ramage G, VandeWalle K, . Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother 2003; 47: 3657–3659.
   PubMed Web of Science ®Google Scholar
• Pai MP, Samples ML, Mercier RC, Spilde MN. Activity and ultra-structural effects of antifungal combinations against simulated Candida endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 2367–2376.
   PubMed Web of Science ®Google Scholar
• Shuford JA, Piper KE, Steckelberg JM, Patel R. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. Diagn Microbiol Infect Dis 2007; 57: 277–281.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Ohno H, Imamura Y, . The effects of an Hsp90 inhibitor on the paradoxical effect. Jpn J Infect Dis 2009; 62: 392–393.
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773–1780.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for-Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard M27-A. Wayne, PA, (National Committee for Clinical Laboratory Standards, 1997).
   Google Scholar
• Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081–3088.
   PubMed Web of Science ®Google Scholar
• Cao YY, Cao YB, Xu Z, . cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother 2005; 49: 584–589.
   PubMed Web of Science ®Google Scholar
• Karababa M, Valentino E, Pardini G, . CRZ1, a target of the calcineurin pathway in Candida albicans. Mol Microbiol 2006;59:1429–1451.
   PubMed Web of Science ®Google Scholar
• Cowen LE, Singh SD, Kohler JR, . Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009; 106: 2818–2823.
   PubMed Web of Science ®Google Scholar
• Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science 2005; 309: 2185–2189.
   PubMed Web of Science ®Google Scholar
• Lenardon MD, Lesiak I, Munro CA, Gow NA. Dissection of the Candida albicans class I chitin synthase promoters. Mol Genet Genomics 2009; 281: 459–471.
   PubMedGoogle Scholar
• Wiederhold NP. Attenuation of echinocandin activity at elevated concentrations: A review of the paradoxical effect. Curr Opin Infect Dis 2007; 20: 574–578.
   PubMed Web of Science ®Google Scholar
• Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: Reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 3407–3411.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Riley J, Koerner T. Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. Diagn Microbiol Infect Dis 1990; 13: 31–35.
   Google Scholar